Plus   Neg

Wesfarmers Optimistic About Group Outlook - Quick Facts

Wesfarmers (WES.AX,WFAFF.PK) stated that the Group remains optimistic about the outlook for the Group. The Group said the majority of its retail businesses have seen an improvement in sales growth relative to the second half of fiscal 2019.

Wesfarmers said, in recent months, the Group has seen a modest improvement in retail conditions. The Group noted that weather conditions and successful execution during the important Christmas period will impact sales performance for the year.

"Our businesses face a number of cost headwinds this year, largely as a result of higher personnel costs from new enterprise agreements, increased investment in digital and technology and the impact of a lower Australian dollar on costs of goods sold. These pressures will be offset through productivity and sales growth benefits over time but will have an impact on earnings growth in the near term," Managing Director stated.

Regarding remuneration matters, Wesfarmers said it believes the new remuneration structures will serve shareholders well in the long run. The Group said it will be looking at how to address concerns expressed by shareholders going forward without compromising its long-term focus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT